Post- Myocardial Infarction Arterial Wall Improvement by Low-dose Fluvastatin and Valsartan

• Status: Completed
• Trial end date: 2014-11-01
• Target enrollment: 0
• Participant gender: Male

Summary

The concept of improving arterial wall characteristics by treatment with a very low-dose combination of fluvastatin and valsartan (low-flu/val) in stable, post-myocardial infarction (MI) patients was tested. The parameters of endothelial function (flow mediated dilatation (FMD), reactive hyperemia index) and arterial stiffness (carotid-femoral pulse wave velocity (cf-PWV), local carotid PWV and β-stiffness coefficient) were measured before and after 30 days of treatment, and the residual effect was assessed 10 weeks later. So the investigators explored whether low-flu/val added "on-top-of" optimal therapy could improve endothelial function and arterial stiffness in post-MI patients. Since these improved parameters are well-known predictors of future coronary events, such treatment could decrease cardiovascular risk.

• Phase: N/A

Details

• Lead Sponsor: University Medical Centre Ljubljana
• Treatments: Fluvastatin; Valsartan

Criteria

Inclusion Criteria:

• history of MI in the last 0.5 to 5 years

• males

• aged under 55 years

Exclusion Criteria:

• diabetes mellitus

• manifest peripheral artery disease or carotid artery disease

• acute infection

• chronic diseases

• present therapy with fluvastatin and/or valsartan.